Content area

Abstract

Abstract

Rationale

The effects of hypnotics on automobile driving have been attracting increasing attention. However, few driving simulators (DSs) have been confirmed to have acceptable reliability and validity for assessing the next-day residual effects of zopiclone as a positive control on driving performance.

Objective

To investigate whether a new DS could permit detection of the next-day residual effects of zopiclone on driving performance.

Methods

In this double-blind, randomized, placebo-controlled crossover trial, 28 healthy males received zopiclone 7.5 mg at bedtime on days 1 and 8 and placebo on the other days over a period of 16 days. The participants took part in three driving tasks—road-tracking, car-following, and harsh-braking—using a DS on days 2 and 9 at 9-h post-dosing. Scores on the Karolinska Sleepiness Scale and Profile of Mood States-Second Edition were then assessed, as was the serum concentration of zopiclone.

Results

The estimated differences in the standard deviation of lateral position (cm) in the road-tracking task between the zopiclone and placebo groups on days 2 and 9 were 3.75 cm (90% confidence interval (CI): 1.71–5.79) and 4.07 cm (90% CI: 2.02–6.11), respectively. The estimated differences in the distance coefficient of variation in the car-following task and in the brake reaction time in the harsh-braking task between the zopiclone and placebo groups on day 2 were 4.31 (90% CI: 1.94–6.69) and 24.6 ms (90% CI: 12.7–36.4), respectively.

Conclusions

The DS used in this study has sufficient sensitivity to detect the next-day residual effects of zopiclone on driving performance.

Details

Title
Residual effects of zopiclone on driving performance using a standardized driving simulator among healthy volunteers
Author
Iwamoto Kunihiro 1   VIAFID ORCID Logo  ; Iwata, Mari 1 ; Kambe Daiji 2 ; Imadera Yumiko 2 ; Tachibana Naoki 2 ; Kajiyama Yu 2 ; Ando Masahiko 3 ; Ozaki Norio 1 

 Nagoya University, Department of Psychiatry, Graduate School of Medicine, Showa, Nagoya, Japan (GRID:grid.27476.30) (ISNI:0000 0001 0943 978X) 
 Taisho Pharmaceutical Co., Ltd, Tokyo, Japan (GRID:grid.419836.1) (ISNI:0000 0001 2162 3360) 
 Nagoya University Hospital, Department of Advanced Medicine and Clinical Research, Nagoya, Japan (GRID:grid.437848.4) (ISNI:0000 0004 0569 8970) 
Pages
841-850
Publication year
2022
Publication date
Mar 2022
Publisher
Springer Nature B.V.
ISSN
00333158
e-ISSN
14322072
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2635106404
Copyright
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022.